Total Payments
$20,416
2024 Payments
$4,080
Companies
64
Transactions
313
Medicare Patients
3,511
Medicare Billing
$334,901
Payment Breakdown by Category
Consulting$9,483 (46.4%)
Food & Beverage$5,584 (27.4%)
Other$3,440 (16.8%)
Travel$1,695 (8.3%)
Education$214.34 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,483 | 7 | 46.4% |
| Food and Beverage | $5,584 | 286 | 27.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,440 | 2 | 16.8% |
| Travel and Lodging | $1,695 | 9 | 8.3% |
| Education | $214.34 | 9 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $5,694 | 34 | $0 (2024) |
| Exelixis Inc. | $3,942 | 8 | $0 (2019) |
| Cardinal Health 414, LLC | $2,577 | 7 | $0 (2017) |
| GENZYME CORPORATION | $1,835 | 8 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,242 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $644.71 | 31 | $0 (2024) |
| PFIZER INC. | $485.89 | 25 | $0 (2024) |
| Incyte Corporation | $374.36 | 4 | $0 (2023) |
| Janssen Biotech, Inc. | $327.06 | 14 | $0 (2024) |
| ABBVIE INC. | $305.77 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,080 | 104 | Bayer Healthcare Pharmaceuticals Inc. ($1,221) |
| 2023 | $808.22 | 38 | AstraZeneca Pharmaceuticals LP ($136.61) |
| 2022 | $4,868 | 37 | AstraZeneca Pharmaceuticals LP ($2,582) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $99.10 | 6 | Seagen Inc. ($24.40) |
| 2019 | $2,495 | 49 | Exelixis Inc. ($1,791) |
| 2018 | $2,999 | 42 | Exelixis Inc. ($2,140) |
| 2017 | $5,055 | 36 | Cardinal Health 414, LLC ($2,577) |
All Payment Transactions
313 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Oncology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $30.88 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $122.88 | General |
| Category: Oncology | ||||||
| 11/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: Oncology | ||||||
| 11/01/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 10/29/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), YONSA | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: Oncology | ||||||
| 10/28/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.83 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Spectrum Pharmaceuticals Inc. | ROLVEDON (Drug) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.81 | General |
| 10/16/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $30.22 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.75 | General |
| 10/09/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: Immunology | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Oncology | ||||||
| 10/03/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 785 | 1,496 | $337,882 | $95,868 |
| 2022 | 8 | 824 | 1,164 | $219,863 | $79,967 |
| 2021 | 10 | 877 | 1,247 | $214,441 | $85,320 |
| 2020 | 10 | 1,025 | 1,387 | $213,805 | $73,746 |
Total Patients
3,511
Total Services
5,294
Medicare Billing
$334,901
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 166 | 495 | $122,760 | $35,887 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 216 | 374 | $63,580 | $18,261 | 28.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 88 | 208 | $43,888 | $12,320 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 61 | 82 | $26,814 | $8,953 | 33.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 71 | 71 | $26,199 | $6,435 | 24.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 69 | 152 | $20,672 | $5,623 | 27.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 77 | 77 | $19,173 | $3,899 | 20.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 26 | 26 | $11,726 | $3,401 | 29.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $3,070 | $1,090 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 306 | 580 | $112,690 | $42,009 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 267 | 320 | $41,840 | $14,922 | 35.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 86 | 86 | $22,302 | $8,573 | 38.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 53 | 63 | $16,323 | $7,034 | 43.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 54 | 54 | $11,115 | $3,110 | 28.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 19 | 19 | $7,849 | $2,594 | 33.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 24 | 26 | $5,616 | $1,288 | 22.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 15 | 16 | $2,128 | $437.16 | 20.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 288 | 576 | $100,007 | $42,250 | 42.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 245 | 314 | $39,350 | $15,711 | 39.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 88 | 88 | $20,580 | $8,669 | 42.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 50 | 52 | $13,444 | $5,904 | 43.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 75 | 75 | $12,312 | $4,282 | 34.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $6,406 | $2,567 | 40.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 44 | 47 | $7,118 | $1,784 | 25.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 17 | $3,550 | $939.59 | 26.5% |
About Dr. Karim Anwar, M.D
Dr. Karim Anwar, M.D is a Hematology & Oncology healthcare provider based in Jasper, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053350140.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Karim Anwar, M.D has received a total of $20,416 in payments from pharmaceutical and medical device companies, with $4,080 received in 2024. These payments were reported across 313 transactions from 64 companies. The most common payment nature is "Consulting Fee" ($9,483).
As a Medicare-enrolled provider, Anwar has provided services to 3,511 Medicare beneficiaries, totaling 5,294 services with total Medicare billing of $334,901. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Jasper, IN
- Active Since 06/05/2006
- Last Updated 11/12/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053350140
Products in Payments
- Cabometyx (Drug) $3,942
- IMFINZI (Biological) $3,050
- IMFINZI (Drug) $2,156
- SARCLISA (Biological) $1,810
- Stivarga (Drug) $1,221
- KEYTRUDA (Biological) $280.23
- KISQALI (Drug) $274.24
- EPKINLY (Drug) $230.73
- ADCETRIS (Biological) $197.55
- DARZALEX (Biological) $188.78
- TAGRISSO (Drug) $176.56
- DOPTELET (Drug) $115.46
- LYNPARZA (Drug) $114.99
- XTANDI (Drug) $111.02
- BRUKINSA (Drug) $99.33
- Lenvima (Drug) $92.81
- OPDIVO (Biological) $90.01
- VERZENIO (Drug) $86.30
- INLYTA (Drug) $84.08
- CALQUENCE (Drug) $84.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.